The CONFIDENCE to Live Each Moment
At Alladapt, we believe every person with food allergy deserves to experience more of life’s magical moments with less fear and greater confidence.
To enable this vision, our team of industry-leading scientists and biotechnology professionals is intensely focused on the development of prescription therapeutics for the treatment of food allergy.
Leveraging the growing body of knowledge on the underlying biology of food allergy, we are advancing our mission of developing a single therapeutic to support the management of a broad range of common food allergies.

About Us

We are dedicated to developing and commercializing effective and broadly applicable interventions for food allergy.

Food allergy is a disease of the immune system that is triggered by an exceptionally broad range of commonly allergenic foods such as cow’s milk, eggs, tree nuts, peanuts, shellfish and even sesame. In a perfect world, the human immune system would adapt to all foods. However, in tens of millions of people, the immune system wrongly recognizes some food proteins as harmful and does not adapt. We envision a world where, with help from oral immunotherapy, the immune system can adapt to nearly all food allergens. And we built our inspiration into our name—Alladapt.

Alladapt was co-founded in 2018 in Palo Alto, California, by allergist and protein biochemist Kari Nadeau, MD, PhD, and biotechnology entrepreneur, Ashley Dombkowski, PhD. Academic clinical research conducted by Dr. Nadeau has demonstrated that a food allergic immune system in an individual person can be receptive to remodeling by gradually increasing exposure, under tightly controlled clinical supervision, to the proteins that activate the inappropriate cascade of reactions. This work, combined with research illuminating disease mechanisms and pathways, led the founders to envision a biopharmaceutical intervention capable of addressing food allergy provoked by a wide-ranging set of antigens.

Food allergy is a serious disease, with potentially life-threatening consequences. The disease has grown dramatically in recent years and now affects more than 6 million children¹ and 26 million adults² in the United States alone. Importantly, about half of people with food allergy are reactive to multiple foods, which further increases the risk of anaphylaxis due to accidental ingestion.

The chronic, unpredictable components of this disease can elevate anxiety in patients and their families, and place extreme limitations on their lives. It is our goal to help patients experience more of life’s magical moments with less fear and greater confidence.

¹ Gupta, R. S., Warren, C. M., Smith, B. M., Blumenstock, J. A., Jiang, J., Davis, M. M., et al. (2018). "The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States." Pediatrics 142(6).

² Gupta, R. S., Warren, C. M., Smith, B. M., Jiang, J., Blumenstock, J. A., Davis, M. M., et al. (2019). "Prevalence and Severity of Food Allergies Among US Adults." JAMA Netw Open 2(1): e185630.


Food allergy is a disease that can be triggered by an expansive set of antigens. We are developing an oral prescription therapy with this in mind.

ADP101, our lead drug candidate, is being developed for the mitigation of food allergy provoked by either single or multiple proteins from a wide-ranging set of foods. We are working to formulate this proprietary oral immunotherapy drug candidate as a single agent capable of delivering highly-consistent, well-characterized, precisely-dosed protein from the vast majority of commonly allergenic protein families. ADP101 is based on an intellectual property estate that includes patents and accompanying clinical data licensed from Stanford University.

Presentations and Publications

--Ashley to consider adding list of presentations and publications--

Since 20XX, many publications have focused on food allergy as a single disease...

-- List of presentations and publications --


We strive to understand the needs of the patient community.

We bring an unwavering commitment to collaborating with patients, family members and physicians so that the values and needs of stakeholders in the food allergy community can be incorporated into our program. Our foundational research was originally inspired by insights shared with us by patients and families who were frustrated by the absence of adequate treatment options for such a serious disease. Our outreach revealed:

  • Food allergic patients must avoid a larger set of trigger foods than typically recognized by society, thereby increasing the challenges of keeping patients protected
  • Food allergic patients are increasingly reactive to multiple trigger foods, appearing in many different combinations
  • In addition to the immune components of food allergy, the psychological and social dimensions of the disease must be taken into consideration in order to truly align with patient needs

These insights, and the voices of patients, are at the heart of everything we do at Alladapt.

In an effort to support food allergy advocacy and advance a broader understanding of this serious and complex disease, we have compiled the following links. Whether you are a patient, a family member, or someone seeking a better understanding of this disease, these resources may be useful. Please note these links will take you away from the Alladapt website to sites that are maintained by independent groups.



Clinical Trials

The Harmony Study

The Harmony Study is a Phase 1/2 trial evaluating ADP101, an investigational oral immunotherapy, for the treatment of food allergy. The study is fully enrolled and includes patients with one or multiple food allergies. Learn more at The Harmony Study website or at

Presentations and Publications

--Ashley to consider adding list of presentations and publications--

Since 20XX, many publications have focused on food allergy as a single disease...

-- List of presentations and publications --

Expanded Access Policy

News, Press & Events

– Coming soon –


– Coming soon –

Select Press Coverage

– Coming soon –


Alladapt Presents at LinkedIn Event - A Conversation With Alladapt's Co-founders and Hillary Tolle Carter

May 12, 2022


Leadership Team

Our leadership team is dedicated to developing prescription therapeutics that help patients with food allergy.

Ashley Dombkowski, PhD
Chief Executive Officer and Co-Founder
Kari Nadeau, MD, PhD
Scientific Founder
Michael Holfinger, PhD
Chief Technical Officer
Dana McClintock, MD
Chief Medical Officer
Louise Peacock
Chief Regulatory Affairs and Quality Officer
Amelia Milani, MBA
Senior Vice President of Supply Chain and Operations
Amy Sullivan
Senior Vice President of Development Operations
Mei-Lun Wang, MD
Vice President of Clinical Development

Alladapt’s Board of Directors and Advisors bring diverse capabilities and broad expertise that they contribute to our mission.

Board of Directors

Ashley Dombkowski, PhD
CEO, Alladapt
Jim Momtazee
Managing Partner of Patient Square Capital
George Montgomery
Chief Financial Officer at Retromer Therapeutics
Consultant to WestRiver Group
Senior Advisor to Alvarium Investments LLC
Stacey Seltzer
Partner at Gurnet Point Capital
Travis Wilson
Partner at Gurnet Point Capital
Former President and Chief Executive Officer at Stealth BioTherapeutics

Clinical and Scientific Advisors

Title 1
Title 2

Our Values

Grounded in data &
science, we bring
together diverse &
expert voices to
make thoughtful,
balanced decisions.
We believe we can solve
challenging, unprecedented issues
through experimentation,
innovation, and efficiency
in service of our mission.
We are decisive, acting quickly
without compromising credibility
or quality; we are always aware
that our patients do not have the
gift of time, so we accept no
hurdles as we continuously
move forward together.
We act with integrity;
always taking ownership
of our actions and
making choices in
service of our
We operate as one
Alladapt; optimizing
for team, community,
and human


How can we advance the Alladapt mission together?

Thank you! Your submission has been received.
If your submission asks for a reply, we will respond as soon as possible.
Oops! Something went wrong while submitting the form.